知镜 Cognispect · 医学文献与研究工作台

Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial.

Wu S, Liu W, Chen L, Xu Y, Jin J, Chen F, Li J, Hu W, Wu J, Cai Y, Huang Z, Chai X, Shi X, Luo Y, Zeng G, Zeng H, Chen Z, Guo F, Wang L, Wu M, Qu Z, Wang Y, Peng D.
Frontiers in cardiovascular medicine · 2026-09-18 · PMID 42827937

文献摘要

Background The advent of pharmacogenomics-guided antihypertensive therapy represents a paradigm shift in hypertension management. This study aimed to investigate the prevalence of relevant genetic variants among hypertensive patients in Hunan Province, China, and evaluate the efficacy of genotype-directed vs. clinically guided therapy. Methods A total of 2,702 patients with essential hypertension from 14 hospitals were enrolled and evenly randomized to either a control group receiving standard care or an experimental group receiving pharmacogenomics-tailored medication. Genetic variants in seven gene loci ( ADRB1 , CYP2D6 , CYP3A5 , CACNA1C , CYP2C9 , ACE , ADD1 ) associated with five major drug classes were analyzed. Blood pressure and biochemical parameters were assessed at baseline and 4 weeks post-intervention. Results The frequencies of the risk allele frequencies for ACE , CYP2C9 , ADRB1 , CYP2D6 , CYP3A5 , CACNA1C , and ADD1 were 34.3%, 4.8%, 74.8%, 57.3%, 69.8%, 11.9%, and 46.3%, respectively. After 4 weeks, blood pressure significantly decreased in both groups (all P Conclusion These findings highlight the critical role of genetic profiling in antihypertensive drug selection. Personalized treatment based on pharmacogenomics offers a more effective strategy for hypertension management. In the studied Hunan population, angiotensin II receptor blockers and beta-blockers emerged as particularly efficacious options under genotype guidance.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。